In MASH patients, upregulated markers of gut–vascular barrier (GVB) leakage are observed in the colon, where intestinal FXR ameliorates disrupted GVB through the activation of Wnt/β-catenin signaling [151]. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.